84 related articles for article (PubMed ID: 17155893)
1. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Levinson NM; Boxer SG
PLoS One; 2012; 7(4):e29828. PubMed ID: 22493660
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Quintás-Cardama A; Han X; Kantarjian H; Cortes J
Blood; 2009 Jul; 114(2):261-3. PubMed ID: 19414863
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor Trapping in Kinases.
Spassov DS; Atanasova M; Doytchinova I
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542228
[TBL] [Abstract][Full Text] [Related]
4. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Pan C; Olsen JV; Daub H; Mann M
Mol Cell Proteomics; 2009 Dec; 8(12):2796-808. PubMed ID: 19651622
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Araujo J; Logothetis C
Cancer Treat Rev; 2010 Oct; 36(6):492-500. PubMed ID: 20226597
[TBL] [Abstract][Full Text] [Related]
6. Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism.
Wilson C; Agafonov RV; Hoemberger M; Kutter S; Zorba A; Halpin J; Buosi V; Otten R; Waterman D; Theobald DL; Kern D
Science; 2015 Feb; 347(6224):882-6. PubMed ID: 25700521
[TBL] [Abstract][Full Text] [Related]
7. The (near) miracle of therapy in chronic myeloid leukaemia.
Radich JP
Br J Haematol; 2023 Sep; 202(5):919-921. PubMed ID: 37495373
[No Abstract] [Full Text] [Related]
8. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Santos FP; Cortes J
Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064
[TBL] [Abstract][Full Text] [Related]
10. CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions.
Scalzulli E; Carmosino I; Bisegna ML; Martelli M; Breccia M
Curr Hematol Malig Rep; 2022 Dec; 17(6):198-205. PubMed ID: 36264428
[TBL] [Abstract][Full Text] [Related]
11. Explainable drug sensitivity prediction through cancer pathway enrichment.
Tang YC; Gottlieb A
Sci Rep; 2021 Feb; 11(1):3128. PubMed ID: 33542382
[TBL] [Abstract][Full Text] [Related]
12. Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever.
Nyagwange J; Awino E; Tijhaar E; Svitek N; Pelle R; Nene V
Int J Parasitol Drugs Drug Resist; 2019 Apr; 9():80-86. PubMed ID: 30771616
[TBL] [Abstract][Full Text] [Related]
13. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets.
Mogire RM; Akala HM; Macharia RW; Juma DW; Cheruiyot AC; Andagalu B; Brown ML; El-Shemy HA; Nyanjom SG
PLoS One; 2017; 12(10):e0186364. PubMed ID: 29088219
[TBL] [Abstract][Full Text] [Related]
14. Prediction of chemical-protein interactions network with weighted network-based inference method.
Cheng F; Zhou Y; Li W; Liu G; Tang Y
PLoS One; 2012; 7(7):e41064. PubMed ID: 22815915
[TBL] [Abstract][Full Text] [Related]
15. Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data.
Boyce B; Xing L
Clin Investig (Lond); 2011 Dec; 1(12):1695-1706. PubMed ID: 22384312
[TBL] [Abstract][Full Text] [Related]
16. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Quintás-Cardama A; Kantarjian H; Cortes J
Future Oncol; 2006 Dec; 2(6):655-65. PubMed ID: 17155893
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
19. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
